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Disparities in health outcomes between white and minority Americans are a significant and well 
documented challenge in improving equity in healthcare. Two frequently cited explanations are 
discrimination in treatment - doctors treating minority patients differently, and unequal access to care - 
patients being trapped in facilities of inferior quality. I use a new dataset from the Department of 
Veterans Affairs and employ a novel estimation strategy to investigate the sources of the racial gap in 
mortality for chronic heart disease, the most expensive chronic condition in the elderly. I find that 
racial differences in mortality persist even when the quality of clinics and doctors is controlled for. 
Investigating the doctor-patient interaction, I show that doctor quality significantly influences patient 
outcomes. While minority patients visit slightly less competent doctors, this does not explain the large 
gap in survival. Individual doctors are found to treat their patients similarly regardless of race. On the 
patient side, I demonstrate that variation in compliance triggers a racial mortality gap. Differences in 
patient response to treatment significantly alter survival probabilities. Considerable reductions in 
medical costs could be achieved by convincing patients of the importance of strictly following the 
therapy regimen. I estimate that targeting compliance patterns could reduce the black-white mortality 
gap by at least two-thirds. 
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    Research in the last twenty years has uncovered persistent racial differences in health care 
access, utilization, and outcomes. Identifying the underlying causes may help analyze disparities in a 
wider range of economic outcomes that are affected either directly or indirectly through disparities in 
health. For example, good health has been shown to influence wages, labor force participation, and job 
turnover2. Understanding why health disparities exist and what can be done to eradicate them could 
help reduce differences in outcomes between minorities and whites in other areas.  
The explanations of racial differences in health outcomes that have been offered can be 
grouped broadly into three categories: unequal access to treatment, unequal treatment, and unequal 
quality of care available to minorities. There has been significant exploration of the phenomenon, but 
many open questions remain. Are differences in facility and physician quality responsible for the racial 
gap in mortality? Will there be disparities if access and quality of care were equalized? Or does the 
racial gap reflect differences in patient responses to the same quality of care? This paper offers the first 
set of answers. 
A great deal of research has been done to examine the effect of between-facility differences on 
the racial gap in survival. However, no study has investigated what happens within those facilities. 
This study reveals that in an equal-access set-up, within-facility differences are more important. Little 
has been done to assess how differences in doctor quality influence patient outcomes. I show that 
clinician quality is of foremost importance for patient survival. The literature offers conflicting 
evidence on whether doctors treat black and white patients the same. I demonstrate that differences in 
outcomes exist even when patients are treated the same.  
While research has revealed that minorities are served by a small subset of physicians3, there is 
no empirical evidence showing that this sorting leads to inferior outcomes. A legitimate question is: 
would minority patients still match with different physicians if they were given the same access as 
whites? Would they choose lower quality physicians? This is the first paper to investigate doctor-
patient matching and its effects on patient outcomes. It also explicitly accounts for patient input into 
the treatment process and offers a new explanation for within-facility differences in outcomes. 
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    The data set I use is ideally suited to answering these questions. Because there is such wide 
variation in supply of health care between racial groups, it is an empirical challenge to correctly 
identify the sources of disparate outcomes. I address this by studying patients suffering from a 
common condition who are served in an integrated, equal access medical care system. There are 
several advantages of the data set and the institutional setting. 
First, I follow the same cohorts of patients through outpatient and pharmacy encounters for up 
to six years. This allows me to construct measures of both patient compliance with physician 
recommendations and the quality of clinical care. Both factors are shown to significantly influence 
outcomes.  
Second, I examine the effect of observable physician quality indicators on patient survival. 
Common sense dictates that more competent doctors will affect positively their patients’ health, but no 
previous study has identified an action-based measure of physician quality. Physician quality 
indicators derived from patient outcomes are subject to significant bias arising from the patient mix. 
Instead, I define a physician competence measure based on observance of nationally accepted 
standards of treatment and show that within-clinic differences in doctor quality significantly influence 
patient outcomes. 
Third, the data come from the Veterans Health Administration (VHA), which is frequently 
commended for equalizing access to health care for minorities and implementing a fixed salary to limit 
physicians’ financial incentives to over- or under-provide treatment. VHA facilities provide free care 
to all veterans. This institutional set-up eliminates health care access differences between minority and 
white patients.  
The paper focuses on racial differences in death rates after a diagnosis of chronic heart failure 
(CHF). There are several reasons to focus on this condition. First, heart disease is the leading cause of 
death in the elderly and is the most costly single condition in Medicare in recent years (33.2 billion 
dollars in 2007)4. In addition, cardiovascular disease is a major contributor to the mortality difference 
between white Americans and African Americans, accounting for over 40 per cent of the racial gap. 
Third, heart disease is a chronic condition and an Ambulatory Case Sensitive Condition, i.e. expensive 
hospitalizations and rehospitalizations can be avoided with adequate preventive care and disease 
management. Approximately 10 per cent of all inpatient admissions are for CHF and hospitalizations 
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are about twice as frequent in black males as in white males5. Finally, there are clear guidelines for the 
pharmacologic treatment of heart failure that allow me to test whether doctors provide the optimal 
therapy.  
 I document a significant medium-term difference in survival between whites and minorities in 
spite of the Veterans Health Administration’s efforts to equalize the supply of health care. This 
difference cannot be attributed to inferior access to care for black patients. Differences in socio-
economic status account for only 20 per cent of the racial gap in survival. Black patients see slightly 
lower quality physicians, but they go to better clinics. Doctor quality differences account for about 5 
per cent of the survival gap. I show that within the VHA, doctors treat African American and white 
patients the same. The largest difference between races is in the compliance with therapy. Doctor-
patient matching results in lower average doctor quality for minorities, but it helps improve their 
compliance. Further, there is no difference in survival among patients who mostly observe therapy 
prescriptions, so that the recorded racial gap is entirely due to racial differences among non-compliant 
patients.  
Two directions for policy emerge from my findings. First, significant effort is needed to 
improve doctors’ recognition and application of recommended therapies. Second, the mortality gap 
could be greatly reduced by improving patients’ response to therapy. Interventions focused on 
increasing awareness in minority patients could go a long way towards eliminating disparities.  
     The next section examines previous attempts to explain the black-white differences in mortality 
and some hypotheses discussed in the literature. I describe the data and outline the empirical model in 
Sections 3 and 4. Section 5 presents the results and discusses their applicability to the general 
population. Section 6 outlines some implications for policy. Section 7 concludes. 
 
2. Background and previous literature 
 
    Previous studies have found a consistent negative correlation between black race and patient 
outcomes (Institute of Medicine Report, 2000). There are many measurable and unmeasurable factors 
that contribute to better health. There exist physiological differences, such as sickle cell anemia, that 
are known to affect blacks and whites differently6. However, these are largely irrelevant when making 
comparisons in the US population. More pertinent to explaining the differences are ways in which 
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minority and white Americans differ on dimensions other than physiology. For example, there are 
large educational differences in the population over 65 years of age. Forty-seven per cent of black 
males over the age of 65 did not graduate from high school, compared to 22 per cent of whites. 
Similarly, only one third of elderly white males (65-74 years of age) have a disability, as contrasted 
with 43 per cent of elderly blacks. In the population over 74, two thirds of African American males are 
disabled, as compared to one half of the whites. One fifth of them live below the poverty line, but only 
one twentieth of whites can be classified as poor. Finally, recent research suggests that African 
Americans and whites may differ in their preferences for the consumption of health and health care.  
Black race as a factor associated with worse health outcomes is as a catch-all variable reflective 
of socio-economic differences in a multitude of initial and intermediate determinants of final health 
outcomes. These determinants include differences in the initial stock of health, financial barriers to 
accessing preventive care, provider behavior motivated by financial motives, continuity of care 
received, differing attitudes to health seeking and health maintenance, and residential segregation 
implying geographically varying quality of available care. I discuss these factors in more detail below.  
 
2.1 Factors contributing to the racial gap 
Minority patients are more likely to face financial barriers and provider-level financial 
disincentives to better care. In particular, as a consequence of lower SES and insurance rates, more 
complicated and more expensive procedures may be withheld from them. Physicians and hospitals may 
fear that they will not be reimbursed and elect to withhold some treatments from their minority 
patients. Using data from the Veterans Health Administration gets around many of the differences 
stemming from unequal access or financial motives for over- or under-providing care to minorities. 
Institutional barriers to health care provision are minimal and any disparities remaining within the 
VHA are most likely due to other causes.  
Second, African Americans are more likely to experience discontinuities of care. Many do not 
have a regular primary physician, and rely on emergency rooms as primary sources of medical 
attention (Oster and Bindman, 2003). Studies have shown that irregularity and fragmentation of 
medical care lead to less efficient health management and worse outcomes. Poverty, insufficient health 
education and awareness of one’s health needs, distrust in the health system, and institutional hurdles 
to obtaining regular care are some of the underlying reasons discussed in the literature. Again, using 
VHA data alleviates this problem since the system is designed to provider uniform medical care for all.  
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A third explanation of the racial mortality gap is that the quality of health care received by 
minority patients is worse than health care available to whites. Studies have found that doctors who 
treat primarily black patients are less likely to be board certified and more likely to report not being 
able to provide high quality care to their patients. African Americans have less access to high-quality 
specialists and non-emergency hospitalizations. In particular, poorer African Americans are treated by 
lower-quality and lower-volume cardiac surgeons (Bach et al., 2004; Mukamel et al., 2000; 
Rothenberg et al, 2004). Yet, there are no studies relating this differential matching to inferior 
outcomes. This paper argues that in the context of the VHA, physician-patient matching has little 
effect on the quality of care received by minorities and may improve their outcomes.  
   Differences in health inputs between white and minority Americans may translate in disparities 
in health outcomes. Previous research shows that minorities differ in their attitudes towards health and 
the health care system. In a recent paper Charles, Hurst and Roussanov (2007) demonstrate that blacks 
spend about 56% less on health care than whites. They show that about 14 per cent of that gap is 
explained by preferences for “conspicuous consumption”. Some of the attitudes underlying these 
differences in consumption may also contribute to differences in health maintenance. Goldman and 
Smith (2002) show that patients' adherence to prescribed therapy vary significantly with race and 
education. Blacks and less educated individuals are more likely to experience lapses in treatment as a 
result of their own non-compliance with physician recommendations. These lapses are especially 
important for chronic conditions where strict adherence to prescribed therapy can significantly prolong 
life. I confirm that racial differences in compliance with therapy exist in an equal access system. I 
show that these differences are the most pertinent factor in explaining the racial mortality gap.   
Mistrust in the health care system is a potential source of the difference in attitudes. Black 
patients with cardiac conditions are less satisfied with the health care they receive and more likely to 
mistrust the system overall (LaVeist et al., 2000).  Studies have shown that lower use of contraceptives 
among African American women can be related to perceived individual or group discrimination (Bird 
and Bogart, 2003). There may be differences in satisfaction with care and physician-patient 
cooperation based on racial matching. Saha et al. (1999) find that minority patients who see minority 
physicians are more likely to rate physicians highly and to report receiving preventive care. Patients 
holding negative stereotypes about their physicians are less likely to be satisfied with the care they 
receive and less likely to adhere to physician therapy recommendations (Bogart et al., 2004).  
 7 
     Finally, because of residential segregation and lower socioeconomic status, the quality of the 
hospitals, hospital equipment and personnel may be worse in areas predominantly populated by 
minorities. Even if patients are fully insured and maintain a regular schedule of check-ups and 
preventive care, they would have worse treatment and higher mortality because of the quality of the 
facility in which they are treated. I show that differences in death rates within the VA equal-access 
system are not due to lower quality of the facilities serving predominantly minority patients. 
The persistence of these trends after adjusting for SES and regional differences has led to 
several theoretical explanations going beyond sources of disparities that are testable with aggregate 
data. The racial mortality gap could be the result of statistical discrimination, clinical uncertainty or 
stereotyping (Balsa and McGuire, 2002). Clinical uncertainty might contribute to over- or under-
prescription of therapies to black patients because doctors are less aware of the severity or appropriate 
treatment in the minority group. Stereotyping refers to attributing certain qualities to patients based on 
expectations about the average behavior of members of their group. For example, Bogart et al. (2001) 
demonstrate that doctors are less likely to prescribe certain medications to minority patients because 
they expect lower patient compliance. Using data from doctor-patient encounters I show that there is 
no evidence of such statistical discrimination in the VA health care system.  
 
2.2 Within- and between-facility differences 
In the context of conditions like chronic heart failure, where care is primarily received by 
patients on an outpatient basis, the relative contributions of within- and between-hospital racial 
differences are especially important, since they point to where interventions could be most effective. 
Previous studies diverge in assessing the relative contributions of within- and between-hospital racial 
differences in care to the survival gap.  
A major problem is that data are rarely recorded for the physician-patient pairs which form 
during an encounter. This is impossible in a hospital setting, where the patient is attended to by a 
number of staff. Empirical work assigns the remaining gap after controlling for hospital quality to 
within-hospital differences. Clearly, this is insufficient if the goal is to pinpoint the major source of 
disparities. The data I use enable the construction of physician-patient pairs that are used to study 
individual doctor-patient interactions. 
Research on racial disparities in cardiac care has concentrated on patients who suffer heart 
attacks (acute myocardial infarctions, or AMI). Recent studies have found that a substantial part of the 
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racial disparity in treatments is accounted for by the specific hospital to which patients are admitted 
(Bradley et al. 2004; Barnato et al. 2005; Skinner et al., 2005). Skinner et al. (2005) find large 
between-hospital differences in the treatment of AMIs and yet a substantial fraction of the aggregate 
differences remains unexplained. They suggest that factors such as the quality of physicians may 
explain the remaining difference within hospitals. For example, if white physicians communicate more 
effectively with white patients, this would translate into more adequate treatment for white patients at 
all hospitals (Balsa and McGuire (2003)). 
     The trouble with using 30-day, 6 months, or 1 year mortality rates from AMI to estimate within 
versus between hospital sources of disparities is that patients being treated in emergency conditions are 
assigned doctors randomly at least in the first (and crucial) hours after the AMI. Hence the differences 
in mortality rates are largely driven by the differences in average doctor and equipment quality 
between hospitals. It is harder to pick up the effects of subsequent, post acute-stage patient sorting into 
different providers and variations in the response to treatment. Concentrating on a chronic condition, 
which requires regular interactions and follow-up between doctors and patients is one way to capture 
the outcomes of these processes.   
     A substantial advantage of this paper is that I can track the sequence of doctors that patients 
encounter over time. I use a sample of patients with chronic heart failure (CHF, or congestive heart 
failure, or heart failure) - a chronic and eventually fatal condition. This illness is managed on an 
outpatient basis by primary care physicians. These patients are treated in an equal-access integrated 
health care system, where financial incentives for patients and doctors and greatly reduced. The 
Veterans' Health Administration (VHA) provides free health care for all eligible veterans. The VHA's 
physicians are salaried and hospitals and outpatient centers receive funding depending on the number 
of patients treated. Using the population of patients with chronic (congestive) heart failure (CHF) 
treated in the VHA, I avoid many of the complications arising from differences in socioeconomic 
status between races. Any remaining differences by race are more easily attributable to unequal 
treatment by physicians or differences in patients' attitudes to health. 
Substandard care leads to more frequent hospitalizations, lower quality of life, and ultimately 
larger costs. Efforts to address the mounting health care costs for the elderly must start with identifying 
the causes for worsening chronic conditions, especially in the economically disadvantaged populations 
who may wait to address their health needs until covered by Medicare. The VHA is frequently cited as 
a potential model for a future unified, universal access medical system. The remaining disparities in 
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patients’ outcomes within the VHA exist in addition to differences due to unequal access to private 
care.  
 
3. Data  
 
The data in this study were drawn from the VHA Medical SAS inpatient and outpatient datasets, 
the Beneficiary Identification Records Locator Subsystem (BIRLS) death files, the VHA Enrollment 
files, and the Veterans Service Support Administration (VSSA) clinic performance measures database. 
Data on zip codes were extracted from the Census. The data cover all outpatients who were diagnosed 
with chronic heart failure between October 1998 and October 20047. 
Currently, the majority of veterans belong to the age cohorts who served in World War II, the 
Korean War, and the Vietnam War. The median age of all veterans is 55, with veterans comprising the 
majority of all civilian males older than 65. The proportion varies by race. Veterans account for over 
60 per cent of white males older than 65, but only for 37 per cent of black males aged 65-75 and 51 per 
cent of black males aged over 75 (Bureau of the Census 2001). 
Table 1 shows variable means. I restrict the sample to patients who utilized community based 
outpatient clinics at least twice in the first year after CHF diagnosis. These people could be credibly 
identified as outpatients served by the Veterans Health Administration. Of those patients I exclude the 
individuals who did not have complete information on their race that could be verified either across 
visits and/or by using the inpatient datasets and Medicare data. There were 2487 patients whose race 
could not be determined because the different datasets reported it differently. Finally, I restrict the 
sample to male veterans only. Female veterans comprise less than 2 per cent of the veteran population 
in this age group and are arguably different from the average female in that age group. The final 
sample consists of 48972 VHA patients. CHF disproportionately affects elderly people and the military 
had restrictions on enrolling African Americans until the Korean War. This means that blacks are 
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vital status records. 
 10 
underrepresented in this sample compared to the overall veteran population and to the US population 
in general. Black patients comprise about 7.6 per cent of the sample8. 
        VHA data record income, which offers a substantial advantage in controlling for socio-economic 
status. Income is reported on the enrollment forms each year and is used to determine patients' benefits. 
Previous studies control for income using mean or median zip-code income data from the Census 
bureau. However this measure can be misleading especially when the emphasis is on the effect of 
minority status or SES on health. Segregated neighborhoods have wide variations in income. Median 
income would over-estimate the financial means of the minority population and at best provide a crude 
measure of the SES of the zip-code as a whole. 
Because minorities on average have lower socioeconomic status (SES) and tend to delay 
seeking health care, it is likely that private and university-affiliated hospitals seeing a higher 
proportion of black patients are also "sicker" or poorer hospitals. The centralized budgeting system of 
the VA is government-sponsored, hence the SES of the patients does not influence the resources of the 
clinic. Resources are distributed on the basis of the patient load. Clinics that serve a larger proportion 
of patients get more funding. In the VHA physician visits, procedures and hospitalizations are virtually 
free, and prescription drugs heavily subsidized at prices lower than Medicare prices9. Co-payments are 
still in the process of being introduced and are required only from enrollees with the highest SES and 
no service-related conditions. Patients can only obtain prescription medications at subsidized prices if 
those medications are prescribed by a VHA physician. Patients must maintain a primary care physician 
in the VHA.   
Congestive heart failure is a progressive disorder with fatal outcomes. Mortality rates in the 
first year after diagnosis are about 10 per cent. However, if care is managed well, patients' chances of 
living longer and their quality of life can be improved significantly. The recommended medical 
therapy is well publicized. Once the first year of treatment has passed successfully, chances of longer-
term survival increasingly depend on the patients' and doctors' ability to adapt the treatment and 
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lifestyles to counter the progression of the disease. Short-term (one-year) mortality is more likely to be 
influenced by the patient's initial physical condition at diagnosis, while longer-term survival would be 
more sensitive to medical therapy and the ability of the patient and the doctor to coordinate the 
management of the disease.  
No other study so far has followed patients for more than 2 years or considered the effect of 
outpatient care on CHF mortality, both of which I find to be important phenomena. The largest 
estimate of the racial mortality gap in CHF was reported by the CDC - 7.8% 10. This is a very crude 
benchmark of the yearly mortality rate, unadjusted for the number of years since diagnosis or 
differences in access and co-morbidities. The closest estimate of the gap to the one I find (and the only 
other estimate using horizons longer than a year) is reported using Medicare data by Dries at al (1999). 
They find a 3.1 percentage points higher probability of survival for white patients after two years of 
follow-up. I argue that at least two thirds of this mortality gap is attributable to differences in patient 
response to therapy, and not to variations in quality, physician discrimination, or institutional barriers 
to accessing health care.  
     Table 1 also shows that black patients are, on average, about 25 per cent poorer. The 
differences in income reported in the sample are close to those observed in Census data for the same 
age group11. White patients are also more likely to be married. Being married is an indicator of 
stronger social support. Elderly males in particular benefit from having a living spouse. White patients 
are more likely to have a stronger social network as proxied by marital status. Whites in the sample are 
on average they are six years older.  
The VHA outpatient datasets contain data on all coexisting health conditions. I select controls 
for co-existing health problems to correspond closely to the conditions used in constructing the 
Charlson-Deyo index of co-morbidities, which is the standard reference in the health literature 
[Charlson, 1987]12. I do not compute an index, but include the conditions as separate controls. The data 
do not supply an indicator of CHF severity, which is likely to differ across patients. However, there is 
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significant information on other cardio-vascular co-morbidities. CHF usually occurs as a result of, or in 
conjunction with some of these conditions. I therefore include indicators for other cardiovascular 
diseases as proxies for the severity of CHF. 
     The sample covers the period from October 1998 to October 2004. Patients join the sample 
throughout this period. The largest numbers of new patients enter in years 2001 and 2002. This 
coincides with the period of largest expansion of the VHA health care system. There was a significant 
increase in the number of patients per clinic over the examined period. The average number of patients 
per clinic goes up from 33 in 1999 to 117 in 2003. The years 1998 are 2004 are incomplete, since 1998 
includes data from the last three months of the year and 2004 ends in September. A potential concern 
is that the patients joining the VHA health system after 1998 could have an advanced stage of CHF at 
the time of first diagnosis within the VHA. I control for such sources of bias by including cohort 
dummies. Most of the new patients who joined the VHA after 1998 are white patients with higher 
income. Therefore, any discrepancy in severity at first diagnosis would work against finding racial 
differences in survival and would bias the coefficient on black race in the survival regressions 
downwards.  
 I define a physician-patient pair as a match between a patient and a doctor for which I observe 
more than two interactions in the data. Patients see a number of doctors over the course of treatment. 
African Americans see more doctors, but they get fewer prescriptions per doctor, implying that the 
intensity of their relationship with any given physician is lower. Another dimension of this lower 
intensity of interaction is that it takes black patients on average two months longer to first encounter 
their main physician, i.e. the physician who wrote the largest number of prescriptions for them, but the 
chances that the main doctor leaves the clinic in any given month are the same.  
     Clinics vary in size from 1000 visits per year to 300000 visits per year. In this study clinics are 
divided into small (below 10000 visits per year), medium (between 10000 and 20000 visits per year) 
and large (above 20000 visits per year) categories. The ratio of black patients in the clinic is defined as 
the ratio of visits by black patients in a year divided by the total number of visits to the clinic in that 
year13. Black patients are more likely to be treated in large urban clinics (92% in urban and 55% in 
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large clinics), while white patients are more likely to go to small and medium-sized clinics. Table 1 
breaks down the racial profile of the clinic by clinic size and race of the patient. 
 The key variables that I use in the empirical analysis are indicated in bold in Table 1. In the 
next subsections I define those variables that have not been used in the literature before.  
 
3.1 Measuring doctors’ adherence to treatment guidelines 
     I use the prescriptions data and the clinical guidelines set out by the American College of 
Cardiology to evaluate physicians' prescription patterns. The clinical guideline recommends 
prescribing Angiotensin Converting Enzyme inhibitors (ACE inhibitors, or ACEIs) and beta blockers 
(BBs) to all patients with chronic heart failure. Widely publicized clinical trials in the 90s showed that 
patients with CHF benefit from these medications. It has been demonstrated that there drugs improve 
the function of the heart and slow down the progression of the condition. In the early 2000s the VHA 
issued clinical guidelines suggesting to all providers that ACEIs and BBs must be considered in the 
course of therapy. All patients in this sample are eligible because they are diagnosed with congestive 
heart failure. The only exceptions may come from allergies. There is no evidence that black patients 
are more likely to suffer from allergies to ACEIs and beta blockers14.  
     The rate of prescribing the recommended drugs provides an independent benchmark against 
which I can assess the doctor's clinical abilities. The measure of providers' adherence to clinical 
guidelines is constructed as the ratio of patients who encountered the provider in the year and were 
prescribed ACE inhibitors and beta blockers by that doctor over the total number of patients seen by 
the doctor. 
     
Adherence ratio = ((N patients with ACEIs-BBs)/(Total N patients)) 
 
        Since in theory all patients who visit the doctor and have this diagnosis should be prescribed these 
medications, a higher adherence ratio means stricter observance of the recommended therapy. 
Summary statistics by clinic size and race of patient are presented in Table 1. I use the adherence ratio 
as a proxy of doctor quality. Doctor quality and doctor competence are used interchangeably in the 
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 However, at least one guideline suggests that finding the correct dosage may be harder with African American patients 
and hence more careful patient monitoring is advised. 
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text. This measure is directly estimated from data, and it is based on the actual decisions taken by the 
physician. While it is a popular measure in constructing hospital quality indices, it has not been used  
in outpatient data before. It is a better proxy for quality than, for example, indexes based on patient 
outcomes or board certification scores, because the former reflect biases from the patient mix and the 
latter are divorced from the practical side of physician competence. Another salient feature of the 
adherence ratio is that doctor quality measured in this way can be affected by policy. “Quality” in the 
sense used here thus refers to the doctor’s abilities as a clinician, and does not explicitly measure other 
possibly relevant, but unmeasurable doctor characteristics such as cultural competence.  
 
Measuring mean doctor quality per patient 
Patients see more than one doctor every year. I calculate the weighted mean of doctor quality 
for every patient is calculated. The weights are based on the number of prescriptions written by the 
doctor for the patient. For example, if a patient has seen two doctors, and he has 5 prescriptions from 
the doctor of quality 1 and 2 prescriptions from the doctor with quality 0, his mean doctor quality is 
5/7. 
 The relative importance of the quality of clinical care for patient health has not been explored 
in outpatient context despite numerous clinical trials showing that medicines recommended in clinical 
guidelines have a significant impact on mortality and morbidity. Most medical care studies are based 
on inpatient data, where it is impossible to identify the treating physician(s). In a hospital setting, a 
patient is seen by a multitude of doctors and it is very problematic to disentangle the parts of the 
therapy directed by different individuals. Moreover, medical therapy is highly personalized and 
depends on the idiosyncratic health needs of the patients. Few medical conditions have developed 
clinical guidelines at the level of CHF. These two problems make measuring the quality of health care 
difficult in the general population. Here I take advantage of the outpatient management of the health 
condition and demonstrate that doctor quality is of foremost importance for patient survival.  
 
Robustness of the doctor quality measure 
A problem arises if doctors of higher quality are matched to patients of better health along 
dimensions not captured by the controls. The coefficients on doctor quality would then be biased 
upwards. Positive matching of doctors to patient populations is more likely at the clinic level, i.e. 
doctors choose a clinic based on the clinic population. It is less likely that doctors would choose 
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patients within the clinic. The upward bias on the doctor quality coefficient arising from doctor-clinic 
matching is addressed by including clinic fixed effects. The inclusion of clinic fixed effects guarantees 
that the effects on patient survival are identified only by the variation across groups of doctors within 
the same clinic, and not by how doctors are distributed among clinics. However, it is still possible that 
doctors are non-randomly matched to patients within clinics.  This is more likely to happen over time, 
i.e. in the course of patient tenure with the clinic both patients and doctors learn about each other’s 
characteristics. I use the quality of the first doctor who prescribed medication for CHF to alleviate the 
effects assortative matching between doctors and patients within clinic15.  
 
3.2 Patient compliance measures 
     A major criticism of the health literature is that while studies evaluate the effect of doctor 
inputs, they rarely account for the effect of patients’ response to physicians’ efforts. Leonard and Zivin 
(2005), in one of the few studies that explicitly account for patient inputs into the health production 
function, show that in traditional societies patients choose between healers and medical doctors 
depending on the relative importance of the physician’s and patients’ efforts in determining outcomes. 
They demonstrate that interventions in which the patient takes a passive role are more likely to be 
performed by physicians. Patient response is especially important for chronic conditions like chronic 
heart failure that are managed on an outpatient basis, and that require an investment of daily effort by 
the patient. One of the conditions for efficient interaction between providers and patients is patient 
compliance with prescribed therapy.  
     I use data on prescription refills to define a measure of patient compliance with therapy. The 
VHA pharmacy data contain a "days supply" variable attached to each prescription, as well as the time 
when the first dose was dispensed and the time of subsequent refills. Using the "days supply" variable I 
can determine whether the prescription was refilled on time. I define a refill as “compliant” if it was 
picked up within 3 days of the expiration of the previous days’ supply16.  The compliance measure is 
                                                 
15
 The education literature offers the closest type of problem to the one discussed here. Studies attempt to estimate the 
importance of teacher quality on students’ performance independently from the effect of schools, selection into schools, and 
students’ family background. Rivkin, Hanushek and Kain (2005) provide an excellent review of the problem in the 
education context and discuss the challenges to obtaining robust empirical estimates of the effect of teacher quality.  
16
 I choose 3 days because I do not observe opening hours of pharmacies in VA medical facilities. Patients whose previous 
supply expires on a Friday would not be able to obtain a re-fill until the following Monday (or Tuesday, for long 
weekends), even though they may have called it in on time. Even if pharmacies maintain weekend hours, some patients 
may be unwilling to go and pick up medications on Saturday or Sunday. Different time windows were considered ranging 
between 1 and 7 days. The results were very similar across measures. 
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defined as the number of prescriptions which were not re-filled on time over the total number of 
prescriptions. The same technique is used to formulate aggregate patient compliance per year and 
individual patient compliance for every patient-doctor pair.  
 
Compliance ratio = ((N prescriptions filled on time)/(Total N prescriptions)) 
 
     Table 1 shows the summary statistics by race for compliance. The average compliance rate in 
the sample is 50%, and black race is associated with a 3% -5% lower rate of compliant refills. In a 
study of HIV patients Goldman and Smith (2002) find that black race is associated with a 33% 
decrease in the probability of strict adherence to therapy. However, their measure of compliance is 
much stricter.  They consider a patient compliant if she had taken all of her HIV medications correctly 
in 7 out of the past 7 days. The measure I use is less stringent. To the extent that I do not observe 
whether medication was taken correctly on the occasions when it was taken, my measure overestimates 
compliance for all patients. This implies that the estimates of the effect of compliance on outcomes 
reported here are more likely attenuated towards zero.  
 
4. Determinants of survival from Heart Failure: Empirical Strategy 
 
     This paper aims to evaluate the effect of clinic and physician characteristics on the racial gap 
in survival from chronic heart failure. All patients who visit the same clinic are subjected to the same 
common clinic quality17. However, if there is assortative matching between patients and doctors, 
patients visiting the same clinic may be treated differently. Patients of the same physician in the same 
clinic could have different outcomes if the doctor treats them differently based on their personal 
characteristics.  
In most general terms, individual survival is influenced by the quality of the clinic, the quality 
of the doctors, the personal characteristics of the patient and interactions between these variables. 
 
 Survival = F(patient characteristics, clinic quality,  provider input, patient response) 
 
                                                 
17
 The vast majority of patients (over 80 per cent) went to the same clinic throughout the observed period. Those who 
changed clinics did so because they moved residence. The VHA strategically locates outpatient clinics so that they serve a 
population within a geographic area. 
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     There are three types of variables in this model: 1) patient characteristics and doctor quality 
which change across patients and time; 2) clinic characteristics such as the clinic location which are 
constant over time; 3) clinic characteristics which change over time. 
     Let Xgtm be a vector of characteristics for patient m who goes to clinic g at time t, including an 
indicator for black race. Let Bgt be a vector of clinic characteristics which vary between clinics and 
years, but have the same value attached to patients in the same clinic in the same year and µ be the 
clinic fixed effect. Variants of a survival model are estimated. The basic model relating patient 




 ygtm = α +βXgtm+ εgtm    
 
Here the coefficient on race would capture some of the omitted variables’ influence on survival 
outcomes and will be biased downward (i.e., more negative) if black patients are treated in worse 
clinics or by worse doctors.  
Next, the basic model is expanded by adding clinic fixed effects to capture the unobserved 
clinic characteristics which do not vary by year. In addition, the ratio of black patient visits per year 
and the total number of patient visits per year are added as controls. Patient cohort dummies are 
included to control for the differing characteristics of patients being diagnosed in different years and 




 ygtm = α +βXgtm+δBgt+ µg + ηt + εgtm    
 
The model is further complicated by adding the mean doctor quality per patient (Dgm) and the 
interaction term between doctor quality and black race. The addition of the interaction term allows me 










The preferred empirical model is: 
 
 P(survival)  = α + β(patient demographics, co-morbidities, physician quality) +   γ(patient 
race∗physician quality) + δ(clinic ratio black) +  year dummies + clinic dummies + ε 
 
     The weighted average quality of the providers per patient is included as a patient-level variable 
in Xgtm.  
I concentrate the analysis on three-year survival horizons. While one-year survival probability 
is a common benchmark in the literature, it is more appropriate for acute conditions such as stroke or 
AMI (acute myocardial infarctions, or heart attacks). Unlike AMIs, Chronic heart failure is a chronic 
condition which may be contained or worsen over time given the prescribed therapy and the patients' 
compliance with it. Longer-term survival horizons are better suited to capture the effect of quality of 
care over time.  
  
5. Survival from Chronic Heart Failure: Results 
 
5.1 Three-year survival 
 
Basic model 
Table 2 reports the results of a linear probability regression of the probability of surviving the 
third year after initial diagnosis, conditional on surviving the first two18. Estimating three-year survival 
probability conditional on two-year survival is intended to partially offset potential differences in 
severity at first diagnosis. Taking a group of patients who have already survived two years of treatment 
selects those patients who have had less severe conditions at first diagnosis. Columns (1)-(4) report 
results from different specifications. In Column (1) I estimate a basic model including only controls for 
age and co-morbidities, similarly to many studies using private care data. I find that on average, black 
patients are 2 per cent less likely to survive the 3rd year of treatment.  
 
Additional socio-economic factors 
                                                 
18
 One- and two-year survival estimates are available from the author. Different specifications were estimated 
including the square of age, as well as using age cohorts rather than a continuous measure of age. These yielded similar 
results. In robustness checks I also ran the estimation excluding different cohorts. The obtained results were similar. A 
logistic regression for model (1) was also estimated and revealed identical estimates.  
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I control for socio-economic factors in the model estimated in Column (2). Differences in 
socio-economic status account for about 22 per cent of the difference in survival. The magnitude of the 
coefficient on the race dummy is reduced. However, a significant negative correlation between black 
race and medium-term survival still exists.   
 
Clinic quality 
Next, I control for clinic quality. In Model 3 I add controls for the ratio of black patients in the 
clinic in every year, the number of visits to the clinic, and a clinic fixed effect. The coefficient on the 
race dummy becomes larger in absolute value and maintains a negative sign. Differences in clinic 
quality do not explain the difference in the survival rate between blacks and whites. Moreover, blacks 
in the VHA visits better clinics on average. Numerous studies using data from the private health care 
system have found the opposite result. Because of geographic segregation, which is also related to 
differences in SES among residential areas, hospitals in predominantly black neighborhoods are 
underfunded and often understaffed. The case is different in the VHA, where clinics are funded on the 
basis of their patient load. These estimation results confirm that using VHA data effectively controls 
for differences in access to quality care and care provision in explaining the black/white mortality gap. 
  
Physician quality measures 
Physician quality matters. Going to a top-quality doctor improves survival by two months in 
any year. The model in Column (4) includes a measure of mean doctor quality per patient. The effect 
of quality is large and statistically significant. Competence levels do vary within clinics, and they have 
an independent effect on survival. However, a surprising result is that including controls for doctor 
competence reduces the coefficient on black race by only 5 per cent, implying that blacks and whites 
are subjected to similar average doctor quality in the VHA.  
African Americans see different doctors, who are of lower quality, but this does not explain the 
difference in survival. Figure 1 shows a histogram of the distribution of black and white patients within 
doctor quality quintiles. Blacks are more likely to see doctors in the bottom and third quintile, and less 
likely to see doctors in the top 2 quintiles. Minority patients go to slightly lower quality doctors, but 
differential sorting is not the driving factor behind lower survival rates. The coefficient on the black 
race dummy in the model in Column (4) is still negative and statistically significant.  
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Doctor quality does not affect whites and blacks in the same way. The regression in Column (5) 
adds an interaction term between doctor quality and black race. The estimates reveal that the difference 
in survival rates captured by the negative coefficient on the black race dummy in previous models is in 
fact due to a difference in the effect of doctor quality by race. Black patients benefit from quality 
doctors half as much as white patients do. Figure 2 plots the coefficients on doctor quintile dummies. 
The omitted category is the lowest quintile. Blacks receive lower benefits at all levels of doctor 
competence, but the largest difference occurs in the middle range of the doctor quality distribution.   
In practical terms this means that reassigning a white patient from doctors with average quality 
mix in the lowest quintile (<0.2) to doctors with average quality in the top quintile (>0.4) will increase 
his chances of survival by 8 per cent. An equivalent exercise for a black patient will increase his 
chances of survival only by 4 per cent. This is a puzzling and unprecedented result in the literature and 
it motivates the rest of the empirical investigation. 
Physician-patient matching could be the cause of this result. Unobserved characteristics of 
doctors, patients, and the doctor-patient pair may determine selection into doctors over the course of 3 
years. This selection could influence blacks and whites differently and drive the result. The quality of 
the first doctor, however, is less likely to be influenced by a selection process. In Table 3 Columns (3) 
and (4) I include the quality of the first doctor instead of the mean doctor quality per patient. The 
results are the same. Black patients benefit from quality about half as much as whites do.  
There are two potential reasons why this is the case. First, high quality doctors may treat 
minority patients differently – a hypothesis I test in the next subsection. Second, black patients may 
react differently to the same doctor quality. This hypothesis is also tested below.  
 
5.2 Do the same doctors treat black and white patients differently? 
I test for differences in treatment using data on doctor-patient pairs. In Table 4 I report a series 
of linear probability regressions estimating the probability that a patient would be prescribed a 
combination of ACE inhibitors (ACEIs) and beta blockers (BBs) by a doctor. Column (1) reports the 
basic specification controlling for black race and co-morbidities only. Based on this specification there 
are no differences in treatment of black patients across doctors. Column (2) adds controls for income 
and marital status. After controlling for SES, on average black patients appear less likely to be 
prescribed the recommended therapy. There are two possibilities. First, they may be treated differently 
by all doctors. Second, they may be seeing a different mix of doctors.  
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Next, I consider the possibility that the same doctors treat patients differently. In Column (3) I 
include doctor fixed effects, which allow me to restrict the test of differential treatment within the 
same doctors and also controls for unobserved doctor characteristics. After controlling for doctor fixed 
effects, blacks and whites are equally likely to be prescribed the same treatment regimen. Two patients 
visiting the same physician are treated equally regardless of race.  
 
5.3 The role of patient compliance 
Using the measure of patient compliance described in Section 3, I test for differences in 
patient’s response to treatment on several levels. I examine yearly compliance by patients across all 
doctors and all medications as an indicator of the average compliance.  
It is possible that some doctors are better at motivating compliance and the patients’ response 
to this skill could vary by race. Patients could match into different doctors on the basis of these 
unobserved skills. For example, doctors with minority backgrounds may be better at motivating 
compliance in black patients, but not so good with white patients and vice versa. If minority doctors 
were scarce and black patients were forced to see white doctors, then their average compliance would 
be lower. Therefore, a measure of patient compliance was constructed for every patient-doctor pair to 
capture such differences in the effectiveness of doctor-patient interaction.  
Black patient comply less with prescribed therapy. Tables 5 and 6 report a series of regressions 
estimating the effect of demographic characteristics on yearly and doctor-specific patient compliance. I 
first examine the yearly compliance of patients and detect a negative association between black race 
and compliance. Having a spouse is associated with higher compliance, but worse family support does 
not explain the difference in compliance with therapy. Within the same clinic, blacks are 3.6 
percentage points less likely to pick up medications on time (Column (3)). Again, differences in clinic 
unobservables in fact increase the magnitude of the race coefficient, suggesting that minority patients 
visit clinics with better average compliance.  
In Table 6 I focus exclusively on individual doctor-patient pairs. It is possible that differences 
between doctors account for the observed black/white differences in the aggregate. There may be 
unobserved doctor characteristics (such as the doctor’s race, gender, cultural sensitivity), that induce 
different compliance rates in minority patients. The difference persists after controlling for unobserved 
doctor characteristics in Model (3) (Table 6). In the preferred specification with doctor fixed effects in 
Column (3) black patients have 5.6 percentage points lower compliance than whites.  
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If black and white patients were restricted to visiting the same physicians, minorities would 
have even lower relative compliance with therapy. The results obtained from the doctor fixed effects 
regressions in Table 4 and Table 6 suggest that if blacks and whites were seeing the same doctors 
within the clinics, they would receive the same treatment, however minorities would be about 40 per 
cent (1.8 percentage points) less compliant than otherwise. Differential sorting is associated with lower 
mean doctor quality for blacks, but it improves average compliance. The counter-intuitive implication 
here is that sending blacks and whites to the same doctors may increase the survival gap through its 
negative effect on compliance.  
Next I examine more closely the types of doctor-patient relationships which trigger the largest 
differences in patient compliance. Figure 4 plots the coefficient obtained on the interaction term 
between black race and the number of prescriptions associated with a doctor-patient pair. I take the 
number of prescriptions as a proxy for the intensity or regularity of the doctor-patient relationship. The 
model estimated is model (3) in Table 6. The solid line traces the interaction coefficient across all 
doctors. The dotted line denotes the average black dummy coefficient in a regression restricted to the 
most frequently visited (main) doctor. The dashed line denotes the average coefficient on the black 
dummy for a regression restricted to the least frequently visited doctor. Black patient compliance is 
between .04 and .08 lower than white patient compliance. There is a U-shaped correspondence 
between the regularity of the doctor-patient relationship and the compliance of the patient. Doctors that 
are seen less often receive relatively more compliant response from minority patients. Providers that 
are seen more often and are more likely to prescribe and oversee the main therapy receive a relatively 
lower patient response from minority patients. Across the board, black race is associated with worse 
patient response to doctor’s therapy choices, and the largest differences occur in high-intensity 
relationships.  
Compliance may vary across different types of medication and the patterns of non-compliance 
may differ with race. For example, more educated patients (who are more likely to be white) could be 
more aware of the various purposes of medications and may selectively comply more with the some 
types than with others. To capture such differences, I construct a separate measure of compliance with 
ACE inhibitors and beta blockers.  
Not all patients received prescriptions for these medications. An estimation of average 
compliance with all medications using the subsample of patients who were treated with ACE inhibitors 
and beta blockers yielded a coefficient on black race -0.035, which is very similar to the coefficient 
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obtained from the identical specification in Table 6 Panel I Column (3) which uses a larger sample of 
patients.  Table 6 Panel II reports the coefficients from linear regressions of average yearly patient 
compliance with ACEIs and BBs. It also shows average compliance with the physicians who 
prescribed the recommended therapy. The minority patients who were prescribed these drugs were 
even less likely to pick up their refills on time as compared to whites. The preferred specification in 
Panel II Column (3) yields a 5.8 percentage points lower compliance estimate for blacks, which in 
relative terms is more than 11 per cent lower than compliance for whites. There are two possible 
reasons. First, African Americans are less likely to comply with therapy-prescribing physicians 
compared to other doctors. Second, there could be doctor-specific unobserved characteristics which 
make blacks less likely to comply with some high quality doctors.  
Table 7 reports the results using patient-doctor pairs. In Column (1) I report compliance with 
all medications for the subsample of patients who got prescribed ACE inhibitors and beta blockers and 
those physicians who prescribed them. The coefficient on black race is -0.062, i.e. minorities comply 
even less with therapy-prescribing physicians for all medications that those physicians prescribe. The 
preferred specification with doctor fixed effects in column (4) yields an even larger compliance gap for 
compliance with ACE inhibitors and beta blockers in particular. Comparing across doctor-patient pairs, 
minority patients show lower compliance with high quality doctors than with others, and comply less 
with the clinically recommended therapy. This is one of the potential reasons why minorities benefit 
less from interactions with high quality doctors, who are more likely to prescribe such drugs. This 
result suggests that increasing doctor quality may in fact decrease patient compliance for minority 
patients.  
The measure of patient compliance used here is fairly broad since it only captures whether a 
patient called in a re-fill on time. But there are many aspects of compliance. Patients might be taking 
the wrong doses, taking the wrong medication, missing doses, or they could be over-medicating. A 
possibility is that being late in requesting a refill might not be as important as how late the patient is. 
For example, missing one day of therapy is less likely to have disastrous consequences than missing 
one week. This is why in addition to the broad patient compliance measure introduced above I report 
the average lapsed time by race in Table 1. When late, black patients are on average one more week 
behind their therapy regimen than whites. It is important to note that the same level of non-compliance 
implies a much larger lapse in treatment for blacks.  
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5.4 The effect of patient compliance on survival 
If patient compliance accounts for the difference in benefiting from doctor quality then 
including a measure of compliance in the survival regressions should reduce the gap in survival. To get 
an idea about the joint effect of compliance and doctor quality I include the patient’s compliance with 
the first doctor who prescribed CHF medication in the medium-term survival regression. This is a 
lagged measure of compliance that is less likely to be influenced by doctor-patient matching on 
unobservables. 
In Table 8 I include a measure of the compliance with the first doctor who prescribed 
medication for CHF. Studies in the medical literature define patients as “compliant” if they obtain 
more than 80% of their re-fills on time (Rossack, 2004; Ostrop et al, 2000).  It is possible that the 
effect is not linear and only the patients who are at the top levels of compliance do better than the rest. 
To test the hypothesis that only the top patients exhibit a benefit I create an indicator equal to one if the 
patient was more than 90 per cent compliant. Column (2) in Table 8 reports the regression estimates. In 
Column (3) I include interaction terms with mean doctor quality and with black race. The interaction 
with black race is positive and important in magnitude, even though it is not statistically significant. 
These results imply that patient compliance with therapy affects mortality in a non-linear binary 
fashion, and the positive effect is restrained to the top levels of compliance. Minority patients who are 
at the top levels of compliance appear especially likely to benefit from strictly following the 
medication regimen.   
Next I divide the sample into compliant and non-compliant patients based on where their 
compliance levels fall relative to the mean. The idea is to test whether the observed lower benefits of 
doctor quality for black patients are isolated for non-compliant patients19. Table 9 reports the results a 
series of regressions on the samples of compliant and non-compliant patients. Dividing the sample in 
this fashion reveals that the observed lower benefit of physician quality for minority patients is entirely 
driven by the non-compliant part of the population. In fact, there are no differences in survival between 
compliant blacks and whites. The negative coefficient on black race appears only in the sample with 
compliance below the mean.  
                                                 
19
 A potential concern is that selection into compliance is influenced by doctor quality. A probit regression of the 
binary compliant/non-compliant indicator on observables shows no significant effect of mean doctor quality on selection 




A valid question is why this effect is restricted to non-compliant black patients. There are 
several possible reasons. First, non-compliance in whites may be different from non-compliance in 
blacks. For example, when late picking up a medication, black patients take longer than whites. 
Moreover, as demonstrated earlier, non-compliance with clinically recommended therapy is even more 
pronounced in minorities that non-compliance with the average medication pick-up. Second, it is 
possible that non-compliance is common for the most physically active whites and the least active 
blacks and so the reasons for non-compliance may be different in the two samples. For example, 
whites are late picking up a medication because they are feeling well, while blacks are late because 
they don’t have the strength to go to the clinic. Third, lower income and weaker social support may 
play a significant role. For example, a white non-compliant patient may have more alternative venues 
of obtaining the medication. Finally, unobserved, but equally important characteristics of compliance 
such as taking the correct dose at the right time and adjusting one’s lifestyle to manage and mitigate 
the effects of CHF may contribute to the difference.  
A comparison between compliant and non-compliant patients by race reveals some patterns that 
lend partial evidence to some of the hypotheses described above. Means and standard deviations are 
presented in Table 10. Both black and white patients of low compliance are less likely to be diabetic. 
Less compliant blacks have fewer cases of some forms of cancer, but more incidence of ischemic heart 
disease. It is unlikely that non-compliance in black patients is due to poverty – the average annual 
income for low-compliant black patients is 17,710 dollars, compared to 17,450 in the compliant group. 
They do not appear any more infirm than the rest of the population and are generally younger by about 
2 years. Overall, across all patients, those who suffer from other chronic conditions such as diabetes 
and/or pulmonary failure are more compliant. The only significant observable difference between non-
compliant blacks and whites is in the extent of the social support network, as proxied by marital status. 
A promising venue for future work is to investigate in more detail the mechanisms leading to 
suboptimal patient response to therapy and whether they differ across groups.   
The results in this section have several important implications. First, minority patients are less 
compliant regardless of who their doctor is. Second, strict patient compliance to the prescribed 
medication regimen yields positive results. Third, should a black patient fall below the mean level of 
patient compliance, he experiences lower benefits from doctor quality. In practice this means that 
sending a non-compliant black patient to the top doctor would result in the same survival benefit as 
sending a compliant black (or white) patient to doctors with mean quality in the second quintile.  
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5.5 Decomposing the survival gap 
The difference in raw three-year survival conditional on two year survival between whites and 
blacks is -0.008. This does not appear a large difference at first, but it should be pointed out that 
minority patients are significantly younger (by 6 years) in this sample. In Table 11 I report the results 
of Oaxaca-Blinder decompositions of the survival gap by race and compliance level. Coefficients for 
white patients are taken as the base. Using white patients as the base asks the question: How well 
would blacks do if they responded to the medical encounter in the same way as whites but also had the 
same characteristics? Negative signs denote an advantage for blacks, positive signs denote advantage 
for whites. Adjusting for age and co-morbidities yields a 2.8 per cent unrealized survival advantage for 
African American patients. If all were equal, and there were no differences by race in the benefits from 
the various factors affecting survival, they would have a 2.8 percentage points higher probability of 
survival than whites. The 2 percentage points unrealized survival potential for blacks after adjusting 
for age and co-morbidities is more meaningful than the raw difference in survival.  
The effects of socio-economic status account for 30 per cent of this difference. If African 
Americans had the same rates of marriage and the same income as whites, and responded similarly to 
factors influencing survival probabilities, they would have 2.2 per cent higher chance of survival than 
whites. Whites also have higher returns to marriage and income, suggesting that the social support 
network operates better for whites than for blacks.  
Adding clinic fixed effects reveals that on average black patients go to better clinics. Mean 
doctor quality is not significantly different between the two groups and in itself does not contribute to 
the black-white survival gap. After accounting for all factors except patient compliance, there is a 1.7 
per cent difference in black-white mortality which is attributable to differences in ways blacks and 
whites respond to different conditions influencing health.  
The raw difference in survival between races in the compliant sample is 1.5 percentage points 
in favor of blacks. After accounting for all observable differences between black and white compliant 
patients, there remains a very small difference of 0.5 percentage points in favor of whites and 
attributable to coefficients. This suggests that there is essentially no difference in the way black and 
white compliant patients respond to factors influencing survival. The important policy implication here 
is that patient compliance serves as a marker that can be used when designing interventions. Low 
patient compliance should be used as a signal that something is not working in the way health care is 
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delivered to the patient, and that break in the process is likely to influence minorities more negatively 
than whites.  
A very different scenario emerges from the sample of non-compliant patients, where African 
Americans and whites show significantly larger differences attributable to coefficients. The raw 
difference in survival probabilities is only 0.3 percentage points in favor of blacks. However, adjusting 
for age and co-morbidities suggests that the difference should instead be over ten times larger in favor 
of minority patients. Adding controls for income and marital status eliminates about 14 per cent of the 
difference due to coefficients. Non-compliant blacks go to better clinics, but they see worse doctors. 
They benefit less from being married, and from clinic and doctor quality. After accounting for all 
patient, doctor and clinic characteristics, the part of the survival gap attributable to coefficients for 
non-compliant patients is more than one and a half times larger than the overall survival gap.  
In summary, there are almost no differences in the way patients from the top half of the 
compliance distribution react to the medical encounter. The observed difference in survival rates 
associated with black race is entirely accounted for by black patients in the lower half of the 
compliance distribution. These patients should be the focus of policy interventions intended to reduce 
the racial mortality gap.   
 
5.6 Applicability to the general population  
The results presented above are based on a sample of veterans utilizing the VA health care system and 
diagnosed with CHF by a VA physician. The VA health care system presents a convenient case study 
and avoids many of the unobservable heterogeneities that plague studies using Medicare data. Yet, it 
caters to a specific population. First, all veterans who were not drafted, have self-selected into the 
military. This selection may have happened differently among whites and minorities. Second, not all 
veterans elect to use the VA health care system and again, selection into the VA health care system 
may differ by racial group. I use data from the Current Population Survey (CPS) and the National 
Survey of Veterans (NSV) to examine the selection process and assess the bias it introduces into the 
results.  
 
Selection into veteran status  
I use the August 2000 CPS Veteran supplement to compare veterans to non-veterans among the white 
and the African American populations. More than half of the male population (56%) over the age of 65 
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had veteran status in 2000. As a group, veterans are more likely to be married and have higher 
educational attainment. African American veterans are equally likely to have a spouse as non-veterans, 
but they have one more year of education on average. White veterans are more likely to be married 
than non-veterans and have a higher educational attainment. Veteran status serves as a mediator of the 
education gap between black and whites, with black veterans being closer to their white counterparts 
than in the rest of the population. Higher education has been found in numerous studies to positively 
influence health, hence the selection into veteran status by African Americans serves to bias the black-
white mortality gap downwards.  
 
Selection into VA care  
The 2001 NSV is a nationally representative survey of veterans that asks several questions 
related to the use of VA care as well as veterans’ health status and chronic conditions. Among patients 
who are eligible for Medicare those choosing to use the VA health care services are less likely to be 
married and have lower education. However, African Americans in VA care have higher educational 
attainment than African Americans who elect not to use it relative to whites. Married individuals are 
less likely to use VA care across races. Similar comparisons apply to the sample of patients who report 
having a heart condition and for those among them who are eligible for Medicare.  
There is a double selection bias likely to reduce the mortality gap observed among veterans 
using VA health care. First, African Americans with military experience have relatively higher 
education than their civilian brothers as compared with whites. Second, while both black and white 
veterans of high education prefer to use health care sources outside the VA, the gap in education 
attainment between users and non-users is larger among whites.   
 
6. Policy implications 
 
Designing and implementing policies that improve physicians’ awareness of clinically 
recommended therapies and patients’ response to therapy will have first-order effect on overall 
mortality and the racial gap in survival. Numerous techniques for improving patient compliance have 
been suggested. However, few offer a cost-benefit analysis of the proposed interventions. Two 
dimensions of such an analysis are offered here – the efficiency gain from better drug regimen 
compliance, and the gains in value of statistical life-years.  
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A well-known quantification of the benefits of better compliance comes from the town of 
Asheville, North Carolina. The Asheville project involved patients with diabetes mellitus, another 
chronic, common, and potentially fatal disease associated with high hospitalization costs and decrease 
in quality of life. The project recruited pharmacists to monitor and assess the compliance of diabetic 
patients over 12 months20. During the next 12 months inpatient claims went down by 40 per cent.  
The annual hospital costs of CHF have been estimated at $8 billion dollars and the overall 
annual cost of managing CHF at $12 to $20 billion dollars (Alexander et al., 1999). Achieving the 
efficiency of the Asheville project would reduce impatient CHF costs by $3.2 billion dollars per year. 
About 550000 new CHF cases are diagnosed annually. The cost of an identical program for heart 
failure patients would be about 400 dollars per patient in the first year of treatment, and the effect 
could last much longer than the initial 12 months. If every patient is given the type of pharmacy 
counseling used in Asheville, the total bill would be 220 million dollars, which is less than 10 per cent 
of the total savings from preventable hospitalizations only.  
Closing the survival gap requires equalizing black and white therapy compliance rates. 
Increasing black patient compliance by 5 per cent and equalizing it with white patients’ compliance 
will reduce absolute medium-term black mortality by 1.5 per cent. Values of statistical life-years range 
between fifty thousand dollars and one hundred and fifty thousand dollars. Increasing mean black 
compliance to the level of white patients could result in expected savings ranging from one to three 
thousand dollars per black patient per year. There are about 700000 African Americans with heart 
failure in the US, and this number is expected to grow to 900,000 by 2010. Potential reductions in the 




Equalizing access for patients and financial incentives for physicians is not sufficient to close 
the racial mortality gap in elderly patients with chronic heart failure. I find that two thirds of the gap 
recorded using Medicare data persist in an equal-access, government-sponsored medical system with 
salaried physicians. Several reasons for this phenomenon are examined. Differences in socio-economic 
status account for less than one third of the remaining gap in survival. While doctor quality is a 
                                                 
20
 Pharmacists were compensated to initially assess patient compliance, evaluate intermediate outcomes and perform 
routine visits lasting no more than 20 minutes. They were paid 75$ for the first pharmacy consultation, 45$ for the 
intermediate, and 20$ for routine visits. 
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significant factor in improving survival probabilities, there is little evidence of sorting of minorities 
into lower quality doctors and it explains only five per cent of the difference in outcomes. Patient-
doctor matching is efficient in improving patient compliance and may counter the effect of lower 
doctor quality through increased patient compliance. I also show that personal or institutional prejudice 
do not account for the observed disparity. Rather, divergent patient responses to provider input appear 
to trigger some of the differences in survival. 
The largest differences between minorities and whites exist in patient compliance with 
prescribed therapy. One obvious policy recommendation is to invest in changing the compliance 
patterns of minority patients. Clearly, more work is needed to identify the reasons behind diverging 
responses to health care and why they affect whites and minorities differently. The key to solving the 
predicament of racial disparities in health, beyond the effects of unequal supply of care, lies in the 
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Tables and Graphs 
 
Table 1: Variable definitions and means; variables not used in previous studies and introduced in this 
paper are in bold 
 White patients Black patients 
Variable Obs Mean Std. Dev. Obs Mean Std. Dev. 
Yearly income 45512 24890 20000 3460 18644 10500 
Age 45512 73 9 3460 67 12 
Married 45512 0.70 0.46 3460 0.50 0.50 
Patient compliance (all) 41436 0.49 0.28 3074 0.53 0.28 
Patient compliance 
(ACEIs-BBs) 
32716 0.56 0.29 2611 0.51 0.29 
N days late with refill 39929 17 18 3152 22 22.5 
 Outcomes 
% Survived the first year 45512 84% 0.37 3460 0.87 0.34 
% Survived the 2nd 
year|surviving 1st 
26365 86% 0.43 2141 0.88 0.41 
% Survived the 3rd 
year|Surviving 2nd 
17681 89% 0.46 1566 0.90 0.44 
 Clinic characteristics 
Ratio black in clinic 45167 5.57% 7% 3455 15.13% 12% 
% in Small clinics 45512 25.53% 44% 3460 16.82% 37% 
% in Large clinics 45512 34.63% 48% 3460 54.57% 50% 
% in Rural clinics 45314 11.77% 17% 3385 7.79% 14% 
 Patient-doctor matching 
Doctor ratio black 40639 0.06 0.078 3243 0.245 0.18 
Mean doctor quality 40639 0.29 0.09 3243 0.28 0.09 
First doctor’s quality 40639 0.34 0.08 3243 0.33 0.08 
Time to meeting main 
doctor 
40639 254 421 3243 303 478 
doctors /year 40639 1.6 0.2 3243 1.8 0.2 
prescriptions/doctor 40639 8.5 0.3 3243 8.2 0.4 
main doctor absent 40639 2.8 3.87 3243 2.8 3.66 
 Small clinics 
Doctor ratio black 10631 0.04 0.06 545 0.28 0.24 
Mean doctor quality 10631 0.3 0.09 545 0.3 0.1 
 Medium clinics 
Doctor ratio black 15775 0.05 0.06 896 0.19 0.008 
Mean doctor quality 15775 0.29 0.087 896 0.28 0.04 
 Large clinics 
Doctor ratio black 14233 0.09 0.09 1802 0.26 0.17 
Mean doctor quality 14233 0.29 0.09 1802 0.27 0.09 
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Table 2: Three-year survival probability conditional on two-year survival. Linear probability models. 
The dependent variable equals one if the patient survived the third year after diagnosis. All standard 
errors are adjusted for clinic-level clustering.  
 
Outcome: Three year survival conditional on two year survival 
 (1) (2) (3) (4) (5) 
      
Black -0.022** -0.017* -0.019** -0.018* 0.036 
 (0.009) (0.009) (0.009) (0.009) (0.034) 
Age -0.005*** -0.005*** -0.005*** -0.005*** -0.005*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Income  0.002 0.002 0.002 0.002 
  (0.002) (0.002) (0.002) (0.002) 
Married  0.029*** 0.029*** 0.026*** 0.026*** 
  (0.007) (0.007) (0.007) (0.007) 
Mean_doc_quality    0.375*** 0.398*** 
    (0.051) (0.052) 
Black*doc_quality     -0.193* 
     (0.107) 
Co-morbidities YES YES YES YES YES 
Cohort FE YES YES YES YES YES 
Clinic FE NO NO YES YES YES 
Constant 1.284*** 1.251*** 1.230*** 1.127*** 1.121*** 
 (0.026) (0.021) (0.037) (0.041) (0.041) 
Observations 11463 11542 11463 11463 11463 
R-squared 0.032 0.034 0.033 0.039 0.039 
Robust standard errors in parentheses 
* significant at 10%; ** significant at 5%; *** significant at 1% 
 
Controls for co-morbidities include: old myocardial infarction, lymphoma, leukemia, pulmonary failure, diabetes, renal 
failure, colon cancer, angina, cardiomyopathy, ischemic heart disease, prostate cancer, liver disease, dysrhythmias, other 
cardiovascular disease, other cancers. 
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Figure 1: Mean doctor quality by patient race. Shaded red indicates white patients, black denotes black 
patients. Doctor quality is measured as the weighted average of the individual adherence measures of 
all doctors who treated the patient during the period. Adherence to clinical guidelines is constructed as 
the N of patients who were prescribed ACEIs and beta blockers/ total N patients treated by the doctor.  
 


















The following were used as cut-off points for doctor quality quintiles: 
1. mean doctor quality≤ 0.21 
2. 0.21 < mean doctor quality ≤ 0.26 
3. 0.26 < mean doctor quality ≤ 0.3 
4. 0.3 <  mean doctor quality ≤ 0.35 
5. 0.35 <  mean doctor quality  
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Figure 2: Effect of doctor quality on patient survival. The top line (red) indicates white patients. The 
lower line (in black) indicates African American patients. Doctor quality is measured as the weighted 
average of the individual adherence measures of all doctors who treated the patient during the period. 
Adherence to clinical guidelines is constructed as the N of patients who were prescribed ACEIs and 
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Table 3: Three-year survival conditional on two-year survival. Linear probability models. The 
dependent variable equals one if the patient survived the third year after diagnosis. All standard errors 
are adjusted for clinic-level clustering.  
 
Outcome: Three year survival conditional on two year survival 
 (1) (2) (3) (4) 
     
Black -0.018* 0.036 -0.019** 0.054 
 (0.009) (0.034) (0.009) (0.04) 
Age -0.005*** -0.005*** -0.005*** -0.005*** 
 (0.000) (0.000) (0.000) (0.000) 
Married 0.026*** 0.026*** 0.027*** 0.028*** 
 (0.002) (0.002) (0.007) (0.007) 
Income 0.002 0.002 0.002 0.002 
 (0.002) (0.002) (0.001) (0.001) 
Mean_doc_quality 0.375*** 0.398***   
 (0.051) (0.052)   
Black*doc_quality  -0.193*   
  (0.107)   
First_doc_quality   0.37*** 0.4*** 
   (0.046) (0.048) 
Black*first_doc_quality    -.21** 
    (0.11) 
Constant 1.127*** 1.121*** 1.125*** 1.12*** 
 (0.041) (0.041) (0.04) (0.041) 
Co-morbidities YES YES YES YES 
Cohort FE YES YES YES YES 
Clinic FE YES YES YES YES 
Obs 11463 11463 11463 11463 
R-squared 0.039 0.039 0.036 0.036 
Robust standard errors in parentheses 
* significant at 10%; ** significant at 5%; * **significant at 1% 
 
Controls for co-morbidities include: old myocardial infarction, lymphoma, leukemia, pulmonary failure, diabetes, renal 
failure, colon cancer, angina, cardiomyopathy, ischemic heart disease, prostate cancer, liver disease, dysrhythmias, other 
cardiovascular disease, other cancers. 
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Table 4: Probability of being treated with recommended therapy of ACE inhibitors and beta blockers 
by a doctor. The unit of observation is the doctor-patient pair. Linear probability models. Controls for 
co-morbidities and year fixed effects included, coefficients not reported. Standard errors are clustered 
at the patient level. 
 
 
Outcome: Probability of being treated with ACEIs and BBs; patient-
doctor pairs 
 (1) (2) (3) 
    
Black -0.003 -0.009* 0.003 
 (0.004) (0.005) (0.006) 
Age  -0.003*** -0.003*** 
  (0.000) (0.000) 
Married  0.005* 0.002 
  (0.0026) (0.002) 
Income  0.003*** 0.001 
  (0.000) (0.0006) 
Co-morbidites YES YES YES 
Cohort FE YES YES YES 
Doctor FE NO NO YES 
Obs 157469 157469 157469 
R-squared 0.0116 0.029 0.027 
Robust standard errors in parentheses 
* significant at 10%; ** significant at 5%; *** significant at 1% 
 
A patient-doctor pair is a match between a patient and a doctor which produces more than 2 prescriptions for the patient.  
Controls for co-morbidities include: old myocardial infarction, lymphoma, leukemia, pulmonary failure, diabetes, renal 
failure, colon cancer, angina, cardiomyopathy, ischemic heart disease, prostate cancer, liver disease, dysrhythmias, other 
cardiovascular disease, other cancers. 
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Table 5: Patient compliance with therapy. All medications, all doctors. Yearly measures. The 
dependent variable is the ratio of compliant re-fills (re-fills which were picked up within 3 days of 
expiration of the supply of medication from the previous re-fill) for all medications. Standard errors are 
clustered at the clinic level. 
 
 
Outcome: Patients’ average yearly compliance; all doctors, all 
medications 
 (1) (2) (3) 
    
Black -0.024*** -0.023*** -0.036*** 
 (0.008) (0.008) (0.005) 
Age 0.000 0.000 0.000*** 
 (0.00) (0.00) (0.00) 
Income  -0.001 -0.000 
  (0.001) (0.000) 
Married  0.008*** 0.006*** 
  (0.0018) (0.0016) 
Co-morbidities YES YES YES 
Cohort FE YES YES YES 
Clinic FE NO NO YES 
Constant 0.079*** 0.076*** 0.042*** 
 (0.014) (0.014) (0.012) 
Obs 43578 43578 43578 
R-squared 0.026 0.028 0.032 
Robust standard errors in parentheses 
* significant at 10%; ** significant at 5%; ***significant at 1% 
 
Controls for co-morbidities include: old myocardial infarction, lymphoma, leukemia, pulmonary failure, diabetes, renal 
failure, colon cancer, angina, cardiomyopathy, ischemic heart disease, prostate cancer, liver disease, dysrhythmias, other 
cardiovascular disease, other cancers. 
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Table 6: Patient compliance with therapy. Patient-doctor pairs. The dependent variable is the ratio of 




A patient-doctor pair is a match between a patient and a doctor which produces more than 2 prescriptions for the patient.  
Controls for co-morbidities include: old myocardial infarction, lymphoma, leukemia, pulmonary failure, diabetes, renal 
failure, colon cancer, angina, cardiomyopathy, ischemic heart disease, prostate cancer, liver disease, dysrhythmias, other 






Outcome: patient compliance with doctors; all medications; 
patient-doctor pairs 
Outcome: patients’ average yearly 
compliance with ACEIs and BBs 
 Panel I Panel II 
 (1) (2) (3) (1) (2) (3) 
       
Black -0.037*** -0.038*** -0.056*** -0.041*** -0.042*** -0.058*** 
 (0.004) (0.005) (0.005) (0.011) (0.01) (0.009) 
Age -0.000 -0.000 0.000*** 0.001*** 0.001*** 0.001*** 
 (0.000) (0.000) (0.000) (0.00) (0.00) (0.00) 
Income  -0.002*** -0.001**  -0.003** -0.002* 
  (0.001) (0.001)  (0.001) (0.001) 
Married  0.000 0.002  0.008** 0.005 
  (0.003) (0.002)  (0.003) (0.0037) 
Co-morbidities YES YES YES YES YES YES 
Cohort FE YES YES YES YES YES YES 
Doctor FE NO NO YES NO NO YES 
Constant 14.811*** 14.314*** 12.391*** 0.514*** 0.515*** 0.486*** 
 (1.511) (1.516) (1.604) (0.023) (0.024) (0.018) 
Obs 121368 121368 121368 34928 34928 34928 
R-squared 0.004 0.004 0.005 0.005 0.005 0.006 
Robust standard errors in parentheses 
* significant at 10%; ** significant at 5%; *** significant at 1% 
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 Table 7: Patient compliance with therapy. Patient-doctor pairs. The dependent variable is the ratio of 
compliant re-fills for every patient-doctor match. Column (1) shows compliance with all medications 
for the sub-sample of doctors who prescribed ACE inhibitors and beta blockers. Columns (2)-(4) have 
compliant with ACEIs and BBs as an outcome variable. Standard errors are clustered at the patient 
level. 
 
Outcome: patient compliance with doctors; patient-doctor pairs; model (1) has all medications; 
models (2)-(4) are for ACEIs and beta blockers only 
 All medications ACEIs-BBs ACEIs-BBs ACEIs-BBs 
 (1) (2) (3) (4) 
     
Black -0.062*** -0.041*** -0.042*** -0.064*** 
 (0.005) (0.006) (0.006) (0.006) 
Age 0.001*** 0.000 0.000 0.001*** 
 (0.000) (0.000) (0.000) (0.000) 
Income -0.001**  -0.002*** -0.001** 
 (0.001)  (0.001) (0.001) 
Married 0.003  0.002 0.003 
 (0.003)  (0.003) (0.003) 
Co-morbidities YES YES YES YES 
Cohort FE YES YES YES YES 
Doctor FE YES NO NO YES 
Constant 9.548*** 17.130*** 16.661*** 13.292*** 
 (1.746) (1.826) (1.835) (1.990) 
Obs 76853 76853 76853 76853 
R-squared 0.006 0.004 0.004 0.005 
Robust standard errors in parentheses 
* significant at 10%; ** significant at 5%; *** significant at 1% 
 
A patient-doctor pair is a match between a patient and a doctor which produces more than 2 prescriptions for the patient.  
Controls for co-morbidities include: old myocardial infarction, lymphoma, leukemia, pulmonary failure, diabetes, renal 
failure, colon cancer, angina, cardiomyopathy, ischemic heart disease, prostate cancer, liver disease, dysrhythmias, other 




Figure 3: Difference in black/white compliance rate by doctor and N prescriptions. Solid line indicates 
plot the black coefficient from regressions of compliance with any doctor at the given level of 
prescriptions. The dotted line plots the black coefficient on from regressions of compliance with the 
most preferred doctor (the doctor with the highest number of prescriptions). The dashed line plots the 
black coefficient from regressions of compliance with the least visited (bottom) doctor. Controls for 
























Table 8: The effect of patient compliance on medium-term survival. Three-year survival conditional on 
two-year survival. All standard errors are adjusted for clinic-level clustering.   
 
Outcome: three year survival probability conditional on two-year survival 
 (1) (2) (3) 
    
Black -0.018* -0.017* -0.021** 
 (0.009) (0.009) (0.009) 
Age -0.005*** -0.005*** -0.005*** 
 (0.000) (0.000) (0.000) 
Income 0.002 0.002 0.002 
 (0.002) (0.002) (0.002) 
Married 0.026*** 0.026*** 0.026*** 
 (0.007) (0.007) (0.007) 
Mean_doc_quality 0.375*** 0.378*** 0.379*** 
 (0.051) (0.051) (0.051) 
Full_compliance  0.018** 0.015* 
  (0.008) (0.009) 
Black*Full_compliance   0.042 
   (0.026) 
Co-morbidities YES YES YES 
Cohort FE YES YES YES 
Clinic FE YES YES YES 
Constant 1.127*** 1.124*** 1.124*** 
 (0.041) (0.041) (0.041) 
Observations 11463 11463 11463 
R-squared 0.039 0.039 0.039 
Robust standard errors in parentheses 
* significant at 10%; ** significant at 5%; *** significant at 1% 
 
Controls for co-morbidities include: old myocardial infarction, lymphoma, leukemia, pulmonary failure, diabetes, renal 
failure, colon cancer, angina, cardiomyopathy, ischemic heart disease, prostate cancer, liver disease, dysrhythmias, other 
cardiovascular disease, other cancers.
Table 9: The effect of different levels of patient compliance by race. Non-compliant is 1 if the patient was below the mean level of 
compliance with his first doctor. Three-year survival conditional on two-year survival. All standard errors are adjusted for clinic-level 
clustering.  
 
Outcome: Three year survival probability conditional on two-year survival 
 Non-compliant patients Compliant patients 
 (1.1) (1.2) (1.3) (2.1) (2.2) (2.3) 
       
Black -0.036** -0.034** 0.057 -0.004 -0.005 0.006 
 (0.014) (0.014) (0.048) (0.016) (0.017) (0.045) 
Age -0.005*** -0.006*** -0.006*** -0.005*** -0.005*** -0.005*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) (0.000) 
Income -0.000 -0.000 -0.000 0.003 0.003 0.003 
 (0.003) (0.003) (0.003) (0.002) (0.002) (0.002) 
Married 0.022** 0.020** 0.020** 0.037*** 0.034*** 0.034*** 
 (0.009) (0.009) (0.009) (0.010) (0.010) (0.010) 
Mean_doc_quality  0.394*** 0.447***  0.358*** 0.361*** 
  (0.076) (0.075)  (0.061) (0.065) 
Black*doc_quality   -0.326**   -0.040 
   (0.162)   (0.146) 
Co-morbidities YES YES YES YES YES YES 
Cohort FE YES YES YES YES YES YES 
Clinic FE YES YES YES YES YES YES 
Constant 1.239*** 1.137*** 1.123*** 1.220*** 1.121*** 1.120*** 
 (0.045) (0.050) (0.051) (0.048) (0.052) (0.052) 
Obs 5194 5194 5194 6269 6269 6269 
R-squared 0.035 0.041 0.042 0.036 0.042 0.042 
Robust standard errors in parentheses 
* significant at 10%; ** significant at 5%; *** significant at 1% 
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Table 10: Observable characteristics of compliant and non-compliant patients by race for the sample of patients who survived two 
years after diagnosis.  
Variable Obs Mean Std. 
Dev. 
Obs Mean Std. 
Dev. 
Obs Mean Std. 
Dev. 
Obs Mean Std. 
Dev. 
 White patients  Black patients  White patients  Black patients  
 Compliant Non-compliant 
Income   6044 22930 16900 392 17450 9080 4639 23250 16630 700 17710 9460 
Marital 6044 0.669 0.470 392 0.474 0.500 4639 0.703 0.457 700 0.501 0.500 
Age 6044 70.89 9.413 392 67.19 11.372 4639 71.47 9.27 700 65.31 11.43 
Colon cancer 6044 0.008 0.091 392 0.013 0.112 4639 0.008 0.089 700 0.009 0.092 
Old AMI 6044 0.049 0.217 392 0.046 0.210 4639 0.057 0.232 700 0.063 0.243 
Angina 6044 0.047 0.211 392 0.046 0.210 4639 0.060 0.238 700 0.067 0.250 
Hernia 6044 0.025 0.157 392 0.041 0.198 4639 0.025 0.155 700 0.016 0.124 
Pulmonary disorders 6044 0.318 0.466 392 0.260 0.439 4639 0.287 0.452 700 0.270 0.444 
Lymphoma 6044 0.001 0.036 392 0.000 0.000 4639 0.002 0.039 700 0.003 0.053 
Leukemia 6044 0.013 0.114 392 0.023 0.150 4639 0.015 0.122 700 0.016 0.124 
Other_cancers 6044 0.055 0.228 392 0.071 0.258 4639 0.055 0.229 700 0.059 0.235 
Prostate Cancer 6044 0.060 0.237 392 0.059 0.235 4639 0.059 0.236 700 0.073 0.260 
Skin/bone cancer 6044 0.010 0.102 392 0.015 0.123 4639 0.012 0.108 700 0.001 0.038 
Liver disorders 6044 0.031 0.174 392 0.033 0.179 4639 0.029 0.168 700 0.031 0.175 
Renal/ disorders 6044 0.143 0.350 392 0.161 0.368 4639 0.134 0.341 700 0.154 0.361 
Diabetes 6044 0.374 0.484 392 0.406 0.492 4639 0.356 0.479 700 0.367 0.482 
Other 
Cardiovascular 
6044 0.106 0.308 392 0.133 0.340 4639 0.100 0.300 700 0.107 0.310 
Dysrhythmias 6044 0.282 0.450 392 0.173 0.379 4639 0.292 0.455 700 0.200 0.400 
Cardiomyopathy 6044 0.074 0.261 392 0.125 0.331 4639 0.077 0.267 700 0.130 0.337 
Ischemic heart 
disease 
6044 0.539 0.499 392 0.398 0.490 4639 0.544 0.498 700 0.453 0.498 
Cohort 6044 1999.5 0.681 392 1999.4 0.662 4639 1999.5 0.674 700 1999.4 0.692 
Table 11: Oaxaca-Blinder decompositions of the survival gap by race and compliance level. 
Coefficients for white patients taken as base. A negative sign means advantage for blacks, a positive 
sign indicates advantage for whites. Decompositions based on the sample of patients who survived two 
years of treatment.  
 
 All patients 






1. Age, co-morbidities -0.008 -0.028 0.02 
2. Line (1) plus income, marital status -0.008 -0.022 0.014 
3. Line (2) plus clinic FE -0.008 -0.025 0.017 
4. Line (3) plus mean doc quality -0.008 -0.025 0.017 
 Compliant patients 
1. Age, co-morbidities -0.015 -0.023 0.008 
2. Line (1) plus income, marital status -0.015 -0.016 0.001 
3. Line (2) plus clinic FE -0.015 -0.02 0.005 
4. Line (3) plus mean doc quality -0.015 -0.02 0.005 
 Non-compliant patients 
1. Age, co-morbidities -0.003 -0.031 0.028 
2. Line (1) plus income, marital status -0.003 -0.027 0.024 
3. Line (2) plus clinic FE -0.003 -0.034 0.031 
4. Line (3) plus mean doc quality -0.003 -0.032 0.029 
  
 
